MEF2D promotes tumor growth, metastasis and angiogenesis, affects tumor cells and even the tumor microenvironment, increases PD-L1 expression in HCC cells, and suppresses CD8+ T cell-mediated antitumor immunity. This evidence concerns the gene MEF2D and hepatocellular carcinoma.